CymaBay Therapeutics
Bookmark
ShareCymaBay Therapeutics is a company. It is in Newark, the United States and it has a male CEO called Sujal A. Shah. It was founded in 1991 and is part of the Health Care sector, specifically in the Biotechnology industry.
Key facts
- city: Newark
- state: CA
- country: United States
- employees: 59 people
- revenues: Try Pro to see estimate
- sector: Health Care
- industry: Biotechnology
- foundation year: 1991
- CEO: Sujal A. Shah
- CEO gender: male
- ESG score: Try Pro to see estimate
- environmental score (ESG): Try Pro to see estimate
- social score (ESG): Try Pro to see estimate
- governance score (ESG): Try Pro to see estimate
See more facts
Extract data
Download datasets about CymaBay Therapeutics:
Dataset of stocks from CymaBay Therapeutics:
CymaBay Therapeutics is one of the companies in Biotechnology, companies in Health Care, companies in Newark, companies in the United States and 3,456,835 companies in our database.
Talking Points
- Gilead Sciences
- Gilead Sciences, a biopharma company, achieves bold ambitions to help make the world a healthier place, leading in HIV, liver disease, cancer & inflammation.
- CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.
